|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Characterization of nucleohistone and nucleoprotamine components in the mature human sperm nucleus显示文摘瞄准:同时决定本地化嘘在内的和鱼精朊人的精原核。方法:核心的 Immunofluorescence 嘘和鱼精朊和染色体 16 的端粒区域的荧光原位杂交在 decondensed 被估计人的精原核。结果:Immunofluorescent 本地化嘘,鱼精朊 1 (PRM1 ) 并且(PRM2 ) 鱼精朊 2 在精原核与染色体 16 telomeric 序列的荧光原位杂交本地化一起揭示了分离分布。对以后的戒指区域局部性的 Histones (即精子原子体环) ,而 PRM1 和 PRM2 看起来在整个全部原子核被驱散。结论:人的核心精子的合作本地化嘘有染色体 16 的 telomeric 区域的与进一个少些压缩的状态的特定的非鱼精朊区域的重组一致。 | Yan Li Claudia Lalancette David Miller Stephen A. Krawetz | 2008 | Asian Journal of Andrology2008，10，4： | 7 |
| 2 | 肝上腔静脉成形术联合肝后腔静脉扩展术在肝移植中的应用:首次115例经验报道显示文摘目的:本文介绍原位肝移植中腔静脉成形术的方法并评估其结果。方法:1994年11月至2000年9月,我们对连续115例原位肝移植(包括6例左外侧叶及2例右叶移植)病人采用了腔静脉成形术。 在起初的4年里,53例(66.3%)移植病人需行股-腋静脉体外转流,而以后的2年内该比例降至8例(22.9%)。无一例病人需中转为背驮式或经典术式。结果:中位手术时间4.5h,中位热缺血时间25min,中位输血量6U浓缩红细胞。上述结果在首次移植及再次移植间无差异。本组无与腔静脉成形技术相关的围手术期死亡。包括活体原位肝移植在内,均未观察到肝静脉流出道梗阻。没有病人因急性肾功能衰竭而需术后血透。病人留置于ICU的中位天数2d,中位住院天数为10d。结论:腔静脉成形术无需解剖肝后腔静脉、肝静脉或肝短静脉,肝下腔静脉也得以保留,并因此更有利于肝切除及维持稳定的血流动力学,在再次移植中优势更为明显。大开口的三角形腔静脉吻合容易操作,能在较短时间内完成供肝植入,且易与吻合血管口径的匹配,并可避免流出道阻塞。操作时间的缩短减少了静脉体外转流的可能。我们认为腔静脉成形技术能适用于所有病人,且相应手术的并发症少。 | You Min Wu Michael Voigt Stephen Rayhili Daniel Kartz Rou-Yee Chenhsu Warren Schmidt Rachel Miller Frank Mtros Douglas Labrecque 周光文 | 2002 | 外科理论与实践2002，7，2： | 7 |
| 3 | Adverse Effects of Low Dose Amiodarone: A Meta-Analysis显示文摘 | Vicken R Vorperian Thomas C Havighurst Stephen Miller Craig T January | 1997 | Journal of the American College of Cardiology1997，，3： | 2 |
| 4 | Composition and Three-Dimensional Architecture of the Dengue Virus Replication and Assembly Sites显示文摘 | Sonja Welsch Sven Miller Ines Romero-Brey Andreas Merz Christopher K.E. Bleck Paul Walther Stephen D. Fuller Claude Antony Jacomine Krijnse-Locker Ralf Bartenschlager | 2009 | Cell Host & Microbe2009，，： | 2 |
| 5 | Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors显示文摘 | Helena A. Yu Camelia S. Sima James Huang Stephen B. Solomon Andreas Rimner Paul Paik M. Catherine Pietanza Christopher G. Azzoli Naiyer A. Rizvi Lee M. Krug Vincent A. Miller Mark G. Kris Gregory J. Riely | 2013 | Journal of Thoracic Oncology2013，，3： | 2 |
| 6 | Anti-hypertensive drugs in children and adolescents显示文摘Worldwide the prevalence of essential hypertension inchildren and adolescents continues to increase. Tradi-tionally providers have used 'off-label' drugs to treatpediatric hypertension, meaning that rigorous clinicaltrials of these drugs have not been specifically per-formed in pediatric patient populations. Consequentlyproviders have extrapolated dosing, safety and efficacyfrom trials in adults. This practice is sub-optimal as chil-dren demonstrate unique differences in drug metabo-lism and response. Use of unstudied or understudieddrugs increases risk of adverse events and/or can leadto sub-optimal efficacy. Recognizing these concerns,regulatory agencies have created financial incentivesfor industry to conduct pediatric clinical trials. Theseincentives, coupled with the emerging pediatric hyper-tension epidemic, have spurred over 30 clinical trialsof anti-hypertensive drugs over the past 15 years andhave resulted in labeling of 10 new drugs by the UnitedStates Food and Drug Administration for treatment ofhypertension in children and adolescents. Unfortunatelythe financial incentive structures focus on newer drugsand drug classes. Consequently there is now a relativedearth of trial data for older but sometimes commonlyprescribed pediatric antihypertensive drugs. This article reviews recent pediatric antihypertensive drug trials with a focus on trial design and endpoints, drug dosing, safety, efficacy and specific drug indications. We also review the available data and experience for some of the more commonly prescribed, but less well studied 'older' pediatric antihypertensive drugs. | Patricia Y Chu Michael J Campbell Stephen G Miller Kevin D Hill | 2014 | World Journal of Cardiology2014，6，5： | 2 |
| 7 | Age-related normal ranges for the Haller index in children显示文摘 | Stephen W. Daunt Justine H. Cohen Stephen F. Miller | 2004 | Pediatric Radiology2004，，4： | 1 |
| 8 | DNA-PKcs and ATM co-regulate DNA double-strand break repair显示文摘 | Meena Shrivastav Cheryl A. Miller Leyma P. De Haro Stephen T. Durant Benjamin P.C. Chen David J. Chen Jac A. Nickoloff | 2009 | DNA Repair2009，，8： | 1 |
| 9 | Survival in patients with severe adult respiratory distress syndrome treated with high-level positive end-expiratory pressure显示文摘 | Stephen M. DiRusso Loren D. Nelson Karen Safcsak Richard S. Miller | 1995 | Critical Care Medicine1995，，9： | 1 |
| 10 | LONG-TERM MEDICAL COMPLICATIONS IN PATIENTS SURVIVING ≥5 YEARS AFTER LIVER TRANSPLANT显示文摘 | Patricia A. Sheiner Joseph F. Magliocca Carol A. Bodian Leona Kim-Schluger Gulum Altaca James V. Guarrera Sukru Emre Thomas M. Fishbein Stephen R. Guy Myron E. Schwartz Charles M. Miller | 2000 | Transplantation2000，，5： | 1 |
| 11 | Fiscal Structures and Economic Growth at the State and Local Level Public Finance Review显示文摘 | Stephen M. Miller | | 0，，3： | 1 |
| 12 | Male sterility in Heliothis virescens x H. subflexa backcross hybrids显示文摘 | Stephen G. Miller Milton D. Huettel Minh-Tam B. Davis Eileen Hickey Weber Lee A. Weber | 1986 | MGG Molecular & General Genetics1986，，3： | 1 |
| 13 | Aqueous amine as reactive solvents for mereaptan removal显示文摘 | Stephen A Bedell MicheUe Miller | 2007 | Ind Eng Chem Res2007，46，11： | 1 |
| 14 | The Safety, Tolerability, and Efficacy of Once-Daily Memantine (28 mg): A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients with Moderate-to-Severe Alzheimer’s Disease Taking Cholinesterase Inhibitors显示文摘 | George T. Grossberg Facundo Manes Ricardo F. Allegri Luis Miguel Gutiérrez-Robledo Sergio Gloger Lei Xie X. Daniel Jia Vojislav Pejovi? Michael L. Miller James L. Perhach Stephen M. Graham | 2013 | CNS Drugs2013，，6： | 1 |
| 15 | Cardiovascular risk in healthy men and markers of oxidative stress in diabetic men are associated with common variation in the gene for uncoupling protein 2 显示文摘 | Dhamrait SS Stephens JW Cooper JA Acharya J Mani AR Moore K Miller G J Humphries S E Hurel S J Montgomery H E | 2004 | Europe heart2004，25，： | 1 |
| 16 | Total factor productivity and the convergence hypothesis 显示文摘 | Stephen M Miller Mukti P Upadhyay | 2002 | Journal of Macroeconomics2002，，24： | 1 |
| 17 | Cutaneous polyarteritis nodosa in children显示文摘 | Basil M. Fathalla Laurie Miller Stephen Brady Jane G. Schaller | 2005 | Journal of the American Academy of Dermatology2005，，4： | 1 |
| 18 | Azetidinones as vasopressin V1a antagonists显示文摘 | Christophe D. Guillon Gary A. Koppel Michael J. Brownstein Michael O. Chaney Craig F. Ferris Shi-fang Lu Karine M. Fabio Marvin J. Miller Ned D. Heindel David C. Hunden Robin D.G. Cooper Stephen W. Kaldor Jeffrey J. Skelton Bruce A. Dressman Michael P. Cl | 2006 | Bioorganic & Medicinal Chemistry2006，，5： | 1 |
| 19 | 显示文摘 | William J Koros Stephen J Miller | 2003 | Journal of Membrane Science2003，，211： | 1 |
| 20 | Executive Function Mech- anism of Theory of Mind 显示文摘 | Ahmend Fayeza Stephen Miller L | 2011 | Journal of Autism and Developmen- tal Disorders2011，，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员